<DOC>
	<DOCNO>NCT00465088</DOCNO>
	<brief_summary>To demonstrate niacin ER simvastatin ( NS ) tablet , compare atorvastatin ( Lipitor® ; Pfizer , Inc. ) , superior high-density lipoprotein cholesterol ( HDL-C ) elevate effect Week 12 subject type II hyperlipidemia mixed dyslipidemia currently lipid-modifying therapy . This prospective , randomize , open-label , blind endpoint ( PROBE ) study .</brief_summary>
	<brief_title>An Open-Label Study Compare Lipid Effects Niacin ER Simvastatin ( NS ) Atorvastatin Subjects With Hyperlipidemia Mixed Dyslipidemia ( SUPREME )</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Subjects must meet follow laboratory criterion : HDLC &lt; 40 mg/dL men &lt; 50 mg/dL woman . LDLC ≥130 mg/dL &lt; 250 mg/dL . TG &lt; 350 mg/dL . Creatine phosphokinase ( CPK ) &lt; 3 x upper limit normal ( ULN ) . Alanine aminotransferase ( ALT ) ; serum glutamic pyruvic transaminase [ SGPT ] aspartate aminotransferase ( AST ) ; serum glutamic oxaloacetic transaminase [ SGOT ] &lt; 1.3 x ULN . Subjects must also reasonably compliant Therapeutic Lifestyle Changes ( TLC ) diet 4 5 week Screening Period prior randomization ( willing comply duration study ) . Subjects history important medical condition abnormality ( specify protocol ) would preclude study inclusion</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>